Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) has a beta value of 1.54 and has seen 1.38 million shares traded in the last trading session. The company, currently valued at $1.75B, closed the last trade at $13.23 per share which meant it lost -$1.15 on the day or -8.00% during that session. The CNTA stock price is -44.29% off its 52-week high price of $19.09 and 41.42% above the 52-week low of $7.75. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.07 million shares traded. The 3-month trading volume is 898.31K shares.
The consensus among analysts is that Centessa Pharmaceuticals plc ADR (CNTA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 6 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Sporting -8.00% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CNTA stock price touched $13.23 or saw a rise of 14.65%. Year-to-date, Centessa Pharmaceuticals plc ADR shares have moved -21.01%, while the 5-day performance has seen it change -16.32%. Over the past 30 days, the shares of Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) have changed -12.03%. Short interest in the company has seen 4.86 million shares shorted with days to cover at 4.53.
Wall Street analysts have a consensus price target for the stock at $27.5, which means that the shares’ value could jump 51.89% from current levels. The projected low price target is $27.0 while the price target rests at a high of $28.0. In that case, then, we find that the current price level is -111.64% off the targeted high while a plunge would see the stock gain -104.08% from current levels.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
The company’s shares have lost -16.21% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -210.04% over the past 5 years. Earnings growth for 2025 is a modest 29.13% while over the next 5 years, the company’s earnings are expected to increase by 6.48%.
CNTA Dividends
Centessa Pharmaceuticals plc ADR is expected to release its next earnings report on 2025-Mar-23 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
Insiders own 1.54% of the company shares, while shares held by institutions stand at 96.14% with a share float percentage of 97.64%. Investors are also buoyed by the number of investors in a company, with Centessa Pharmaceuticals plc ADR having a total of 142.0 institutions that hold shares in the company. The top two institutional holders are MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with over 19.96 million shares worth more than $180.27 million. As of 2024-06-30, MEDICXI VENTURES MANAGEMENT (JERSEY) LTD held 18.233% of shares outstanding.
The other major institutional holder is GENERAL ATLANTIC, L.P., with the holding of over 9.68 million shares as of 2024-06-30. The firm’s total holdings are worth over $87.43 million and represent 8.8427% of shares outstanding.
